Ovarian cancer, the leading cause of cancer-related deaths in women, is a disease with high morbidity and mortality, and limited treatment options. A promising new therapy, involving stem cells, is under development but requires more relevant culture models to be able to translate basic research into clinical applications.
Jellagen Pty Ltd manufactures collagen-based scaffolds for regenerative medicine therapeutic approaches for osteochondral disease. These same scaffolds could be used as culture systems for 3D cell culture, that more accurately replicates the in vivo environment. To define the process engineering and market support systems required to make this product suitable for 3D cancer cell growth, their models require further development.
Research expertise from the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University, and the Regenerative Medicine Institute (REMEDI) at NUI, Galway. Together with advanced oncology, regenerative medicine and cell culture facilities at these institutes, are being focused on a comprehensive development plan for the Jellagen product portfolio.
Partners: Jellagen Pty Ltd, Swansea University & National University of Ireland, Galway.